Literature DB >> 8013027

Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis.

N Nakao1, H Uchida, K Kamino, Y Nishimura, H Ohishi, Y Takayasu, K Miura.   

Abstract

PURPOSE: Multivariate analysis was used to study the effectiveness and optimum dose level of Lipiodol (LP) in transcatheter arterial embolization (TAE) of hepatocellular carcinoma (HCC).
METHODS: A total of 219 cases of nodular type HCC, with a tumor diameter less than 7 cm, were studied. TAE was performed using both Gelfoam sponge (GS) and LP in 158 cases; in the remaining 61 cases only GS was used.
RESULTS: Statistical stepwise variable selection revealed that only LP had a negative T-value, suggesting that LP is a useful factor for prognosis. The most favorable effect on patient prognosis was obtained with an LP dose level (expressed in mm) of 1-1.5 times the absolute value of the tumor diameter (expressed in cm).
CONCLUSION: A significant difference (p < 0.01, log-rank test) in survival was found between the GS with LP group and the GS only group, using Cox's proportional hazard model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013027     DOI: 10.1007/bf00193921

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  10 in total

1.  [Transcatheter oily chemoemobolization of hepatocellular carcinoma using adriamycin, lipiodol and gelfoam: pharmacokinetics of adriamycin].

Authors:  H Nakamura; T Hashimoto; T Taguchi; K Inoue; H Oi
Journal:  Gan To Kagaku Ryoho       Date:  1986-03

2.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

3.  An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies.

Authors:  J Okamura; S Horikawa; T Fujiyama; M Monden; J Kambayashi; O Sikujara; M Sakurai; C Kuroda; H Nakamura; G Kosaki
Journal:  World J Surg       Date:  1982-05       Impact factor: 3.352

4.  A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin.

Authors:  M B Garnick; W D Ensminger; M Israel
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

5.  Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.

Authors:  K Takayasu; Y Shima; Y Muramatsu; N Moriyama; T Yamada; M Makuuchi; H Hasegawa; S Hirohashi
Journal:  Radiology       Date:  1987-05       Impact factor: 11.105

6.  Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma.

Authors:  H Uchida; H Ohishi; N Matsuo; K Nishimine; S Ohue; Y Nishimura; M Maeda; T Yoshioka
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

7.  Transcatheter oily chemoembolization of hepatocellular carcinoma.

Authors:  H Nakamura; T Hashimoto; H Oi; S Sawada
Journal:  Radiology       Date:  1989-03       Impact factor: 11.105

8.  [Large-dose intra-arterial injection of lipiodol in liver cancer].

Authors:  Y Takayasu; M Kotake; M Takehara; M Taniguchi; N Nakao; T Miura; H Nakamura
Journal:  Gan To Kagaku Ryoho       Date:  1988-08

9.  Transcatheter arterial chemotherapy using doxorubicin, iodized oil and Gelfoam embolization in hepatocellular carcinoma.

Authors:  B Van Beers; A Roche; P Cauquil; J Jamart; D Pariente; Y Ajavon
Journal:  Acta Radiol       Date:  1989 Jul-Aug       Impact factor: 1.990

10.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.

Authors:  K Okuda; T Ohtsuki; H Obata; M Tomimatsu; N Okazaki; H Hasegawa; Y Nakajima; K Ohnishi
Journal:  Cancer       Date:  1985-08-15       Impact factor: 6.860

  10 in total
  7 in total

1.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

Review 2.  Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  Chang Soo Choi; Ki Hoon Kim; Geom Seog Seo; Eun Young Cho; Hyo Jeong Oh; Suck Chei Choi; Tae Hyeon Kim; Haak Cheoul Kim; Byung Suk Roh
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

3.  Embolization of liver tumors: Past, present and future.

Authors:  Ashwin Rammohan; Jeswanth Sathyanesan; Sukumar Ramaswami; Anand Lakshmanan; Perumal Senthil-Kumar; Ulagendra Perumal Srinivasan; Ravi Ramasamy; Palaniappan Ravichandran
Journal:  World J Radiol       Date:  2012-09-28

4.  Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity.

Authors:  Takaaki Hasegawa; Haruyuki Takaki; Takashi Yamanaka; Masashi Fujimori; Atsuhiro Nakatsuka; Junji Uraki; Tomomi Yamada; Hajime Sakuma; Koichiro Yamakado
Journal:  Jpn J Radiol       Date:  2013-03-24       Impact factor: 2.374

5.  Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT.

Authors:  Hong-Yan Cheng; Yi Shou; Xiang Wang; Ai-Min Xu; Dong Chen; Yu-Chen Jia
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

6.  Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis.

Authors:  Wei-Fu Lv; Kai-Cai Liu; Dong Lu; Chun-Ze Zhou; De-Lei Cheng; Jing-Kun Xiao; Xing-Ming Zhang; Zheng-Feng Zhang
Journal:  Cancer Manag Res       Date:  2018-10-17       Impact factor: 3.989

7.  Experimental Study on Evaluation of Blood Supply Level and Embolization Ratio of Liver Cancer Based on I-Flow Software.

Authors:  Yong Li; Feifan Zhou; Fang Liu; Meng Wang; Wenge Xing
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.